Brilacidin-Ocular is a novel anti-infective drug to treat bacterial eye infections. Brilacidin-Ocular belongs to a completely new class of antibiotics called defensin-mimetics. The defensin-mimetic antibiotics are modeled after host defense proteins, which are the “front-line” of defense in the human innate immune system. Brilacidin-Ocular kills bacteria in the same manner as the human host defense proteins, and in this regard, can significantly reduce the risk of bacterial resistance.
University of Pittsburgh
- Demonstrated the safety, tolerability and broad activity of Brilacidin-Ocular against clinically important Gram-positive and Gram-negative pathogens, including drug-sensitive and drug-resistant clinical isolate strains of ocular infections.
Iris Pharma – PK Studies
- Brilacidin-Ocular has shown to have a high residence time on the surface of the eye with negligible systemic exposure.
- Effective therapeutic concentrations of Brilacidin-Ocular can be maintained in the eye with infrequent treatments.
The company has identified ocular infections, such as keratitis, as an area of unmet medical need and significant commercial potential. Many topical ophthalmic anti-infective drugs that are used today for keratitis and conjunctivitis have serious limitations due to bacterial resistance and serious side effects. The Company has selected Dr. Reddy’s Laboratories Ltd. for the formulation of this drug.
Currently FDA-approved products for ophthalmic use are Besivance®, Vigamox®, and Zymar®. We believe Brilacidin Ocular to have superior advantages.
